Results 91 to 100 of about 5,781 (240)

Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies

Frontiers in Endocrinology, 2023
BackgroundSplanchnic vein thrombosis due to co-existing metastatic pancreatic neuroendocrine tumour (pNET) and JAK2V617F mutation is a rare condition.Case reportHere we present a case of a young woman with complete remission of a non-functioning grade 2 ...
Lívia Sira, Noémi Zsíros, László Bidiga, Sándor Barna, Zsolt Kanyári, Edit B. Nagy, Nicolas Guillaume, Damian Wild, Katalin Rázsó, Szilvia Andó, István Balogh, Endre V. Nagy, Zoltán Balogh   +12 more
doaj   +1 more source

Prognostic Role of Inflammatory Biomarkers in Gastrointestinal Neuroendocrine Neoplasms: A Cross‐Sectional Study

Health Science Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background and Aims Gastrointestinal neuroendocrine neoplasms (g‐NENs) represent a heterogeneous group of tumors with variable prognoses. Inflammation‐based markers, such as the neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR), have emerged as potential prognostic indicators in various malignancies.
Hoda Mahdavi, Vahid Kaveh, Mahdiye Ijadi Nasrabadi, Mohammad Amin Karimi, Mehdi Azizmohammad Looha   +4 more
wiley   +1 more source

Atypical presentation of pheochromocytoma as acute ischemic stroke and pulmonary embolism, a case report

UroPrecision, Volume 3, Issue 4, Page 272-280, December 2025.
Abstract Background Pheochromocytoma is a rare catecholamine‐secreting tumor that often presents with symptoms such as hypertension, palpitations, and sweating due to excessive hormone production. In some cases, the catecholamine‐induced vasoconstriction and hypercoagulability associated with pheochromocytomas can lead to cerebrovascular accidents and ...
Mohannad N. AbuHaweeleh, Ahmad Yousef Al‐maslamani, Majd A. AbuAlrob, Abdelrahman Elsayed, Mahmoud Altayyan, Osama Khalil, Ahmad Abdulhadi   +6 more
wiley   +1 more source

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development [PDF]

, 2015
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a family of neoplasms with a complex spectrum of clinical behavior. Although generally more indolent than carcinomas, once they progress beyond surgical resectability, they are essentially ...
Alberto Carmona-Bayonas, Alex Teule, Enrique Grande, Isabel Sevilla, Jaume Capdevila, Javier Aller, Javier Arbizu, Maria Quindos, null null, Paula Jimenez-Fonseca, Roberto Garcia-Figueiras, Rocio Garcia-Carbonero   +11 more
core   +3 more sources

Controversies in NEN: An ENETS position statement on nutritional support in neuroendocrine neoplasms

Journal of Neuroendocrinology, Volume 37, Issue 12, December 2025.
Abstract Neuroendocrine neoplasms (NEN) themselves and also their treatment may cause malnutrition, inducing changes in physiological behaviour and eventually leading to increased rates of morbidity and mortality. Malnutrition is a common, under‐recognised and under‐treated condition in patients with NEN, and there are limited data available on the ...
Simona Grozinsky‐Glasberg, Johannes Hofland, Stephanie Alband, Yasmin Chotai de Lima, Adina Croitoru, Wanda Geilvoet, Peter Igaz, Beata Kos‐Kudła, Guenter J. Krejs, Alessandro Laviano, Francesco Panzuto, Anguraj Sadanandam, Ana Paula Santos, Staffan Welin, Rajaventhan Srirajaskanthan, V. Ambrosini, D. K. Bartsch, E. Baudin, N. Begum, E. Christ, J. Cros, T. Denecke, C. M. Deroose, C. Dromain, M. Falconi, N. Fazio, L. Fernandez‐Cuesta, R. Garcia‐Carbonero, A. Grossman, G. Kaltsas, A. Kasajima, A. Kjaer, G. Klöppel, U. P. Knigge, A. Lamarca, S. W. Langer, T. V. Luong, W. Martin, M. McNamara, D. O'Toole, S. Partelli, M. Pavel, A. Perren, R. Salazar, J. Schrader, H. Sorbye, A. Sowa‐Staszczak, E.‐J. Speel, P. Stalberg, M. Tesselaar, E. Tiensuu Janson, M. Tsoli, M. Volante, T. Walter   +53 more
wiley   +1 more source

Metastatic large cell neuroendocrine carcinoma of larynx: Individualizing tumor biology by dual tracer positron emission tomography/computed tomography (68Ga-DOTATATE and 18F-fluorodeoxyglucose) molecular imaging and disease stabilization following 177Lu-DOTATATE peptide receptor radionuclide therapy after initial progression on chemoradiotherapy

World Journal of Nuclear Medicine, 2019
Debate exists on the disease biology and course of primary large cell neuroendocrine carcinoma (LCNEC) of larynx, being classified as a variant of atypical carcinoid by the World Health Organisation-2005 classification, while literature of its aggressive
Sonali Jadhav, Sandip Basu
doaj   +1 more source

CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer [PDF]

, 2019
Background: Molecular targeting remains to be a promising approach in oncology. Overexpression of G protein-coupled receptors (GPCRs) in human cancer is offering a powerful opportunity for tumor-selective imaging and treatment employing nuclear medicine.
Bandholtz, Sebastian, Beindorff, Nicola, Brenner, Winfried, Erdmann, Sarah, Exner, Samantha, Grötzinger, Carsten, Gómez, Juan Daniel Castillo, Hacht, Jan Lennart von, Koziolek, Eva Jolanthe, Niederstadt, Lars, Prasad, Sonal, Reinicke, Sandy, Wagener, Asja   +12 more
core   +1 more source

Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well‐differentiated neuroendocrine tumours of the gastro‐enteropancreatic tract

Journal of Neuroendocrinology, Volume 37, Issue 12, December 2025.
Abstract Grade 3 neuroendocrine tumours (NET G3) represent approximately 20% of high‐grade neuroendocrine neoplasms, and the recent identification of this entity has given rise to many unanswered questions relating to clinical management. The prognosis for these patients is worse than for those with Grade 1–2 well‐differentiated NET, but better than ...
Mairéad G. McNamara, Halfdan Sorbye, Nehara Begum, Emanuel Christ, Nicola Fazio, Lynnette Fernandez‐Cuesta, Rocio Garcia‐Carbonero, Gregory Kaltsas, Atsuko Kasajima, Ramon Salazar, Ernst Jan M. Speel, Andreas Kjaer   +11 more
wiley   +1 more source

Efficacy of ¹⁷⁷Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study

Current Oncology, 2020
Peptide receptor radionuclide therapy (PRRT) has been recently established as a treatment option for progressive gastro-entero-pancreatic neuroendocrine tumors (NETs) including four 200 mCi induction cycles. The purpose of this phase 2 trial is to expand
Golmehr Sistani, Duncan E. K. Sutherland, Amol Mujoomdar, Daniele P. Wiseman, Alireza Khatami, Elena Tsvetkova, Robert H. Reid, David T. Laidley   +7 more
doaj   +1 more source

1186MO A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE followed by surgery for pancreatic neuroendocrine tumors (NeoLuPaNET) [PDF]

, 2023
Stefano Partelli, Luca Landoni, Mirco Bartolomei, Alessandro Zerbi, Chiara Maria Grana, Ugo Boggi, Giovanni Butturini, Riccardo Casadei, Claudio Bassi, Massimo Falconi   +9 more
openalex   +1 more source